This company listing is no longer active
Zymergen Past Earnings Performance
Past criteria checks 0/6
Key information
-13.03%
Earnings growth rate
68.14%
EPS growth rate
| Chemicals Industry Growth | 12.93% |
| Revenue growth rate | -22.05% |
| Return on equity | -154.22% |
| Net Margin | -2,503.04% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Zymergen chief scientific officer to depart as company lays off more employees
Aug 25Zymergen: Ginkgo Bioworks Acquisition
Jul 26Zymergen expands agreement with Octant on developing breakthrough medicines
Jul 14Zymergen Seeks Turnaround But Runway Is Running Low
Jun 03Zymergen: A Humbled Company With A Business On The Ropes
May 23Some Zymergen Inc. (NASDAQ:ZY) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 27
Zymergen Inc. (NASDAQ:ZY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Zymergen: Total Chaos
Dec 09Zymergen: How To Buy A Disaster
Aug 05Analysts Just Made A Major Revision To Their Zymergen Inc. (NASDAQ:ZY) Revenue Forecasts
Aug 05Revenue & Expenses Breakdown
How Zymergen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 15 | -365 | 104 | 0 |
| 31 Mar 22 | 18 | -349 | 107 | 0 |
| 31 Dec 21 | 17 | -362 | 106 | 0 |
| 30 Sep 21 | 20 | -359 | 98 | 0 |
| 30 Jun 21 | 19 | -323 | 95 | 0 |
| 31 Mar 21 | 14 | -281 | 85 | 0 |
| 31 Dec 20 | 13 | -262 | 78 | 0 |
| 31 Dec 19 | 15 | -237 | 85 | 0 |
Quality Earnings: ZY is currently unprofitable.
Growing Profit Margin: ZY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ZY's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ZY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZY is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (20.9%).
Return on Equity
High ROE: ZY has a negative Return on Equity (-154.22%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/23 13:29 |
| End of Day Share Price | 2022/10/18 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zymergen Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Matthew Sykes | Goldman Sachs |
| Sriharsha Pappu | HSBC |